| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The chromogranins are ubiquitous proteins which are co-stored and co-secreted with many peptide hormones. All appear to be powerful inhibitors of endocrine secretions. This poses a problem.
When endocrine glands are involved in the efferent limbs of homeostatic loops, they are message transmitters. The self-inhibition caused by the co-secretion of a chromogranin will, on the face of it, erase the message.
Pairs of counter-regulatory homeostatic hormones also present a problem.
If both members of the pair have clearly defined set points, as suggested by their 'time integral' (or 'growth with time') responsiveness to deviations from set point, then, if the two set points are not exactly the same, one or other member will always register an error, leading, eventually, to an overwhelmingly large and unnecessary response.
Our model eliminates both paradoxes, and emphasizes the importance of counter-regulation and the co-secretion of chromogranins in 'zero steady-state error' (ZSSE) homeostasis.
If hormone A is secreted into the blood in progressively increasing amounts when [Q], the plasma concentration of substance Q, is low, and in decreasing amounts when [Q] is high; and hormone B responds in the opposite manner, then there will be a [Q], designated [Q]p, at which the secretory rate increase, or decrease, of the two hormones is exactly the same.
If, in addition, the secretion of both hormones is stimulated by low plasma chromogranin levels, [Cg], but inhibited by high [Cg] then there will be a different [Q]p for every chromogranin concentration in the blood.
At one of these points (at a unique [Q] and [Cg]) the concentration of neither hormone will increase or decrease. This is the equilibrium point to which, according to our model, the system always returns regardless of disturbances within physiological limits.
This article has been cited by other articles:
|
|
 |
|
  T. Angelone, A. M. Quintieri, B. K. Brar, P. T. Limchaiyawat, B. Tota, S. K. Mahata, and M. C. Cerra The Antihypertensive Chromogranin A Peptide Catestatin Acts as a Novel Endocrine/Paracrine Modulator of Cardiac Inotropism and Lusitropism Endocrinology, October 1, 2008; 149(10): 4780 - 4793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Mazza, A. Gattuso, C. Mannarino, B. K. Brar, S. F. Barbieri, B. Tota, and S. K. Mahata Catestatin (chromogranin A344-364) is a novel cardiosuppressive agent: inhibition of isoproterenol and endothelin signaling in the frog heart Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H113 - H122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Cappello, T. Angelone, B. Tota, P. Pagliaro, C. Penna, R. Rastaldo, A. Corti, G. Losano, and M. C. Cerra Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H719 - H727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Tucker, A Bester, E V Lambert, T D Noakes, C L Vaughan, A St Clair Gibson, and C Foster Non-random fluctuations in power output during self-paced exercise * Commentary Br. J. Sports Med., November 1, 2006; 40(11): 912 - 917. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E V Lambert, A St Clair Gibson, and T D Noakes Complex systems model of fatigue: integrative homoeostatic control of peripheral physiological systems during exercise in humans Br. J. Sports Med., January 1, 2005; 39(1): 52 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-M. Yi, Y. Huang, M. I. Simon, and J. Doyle Robust perfect adaptation in bacterial chemotaxis through integral feedback control PNAS, April 25, 2000; 97(9): 4649 - 4653. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
